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A case of pseudohypoaldosteronism type 1 with a 
mutation in the mineralocorticoid receptor gene
Pseudohypoaldosteronism type 1 (PHA1) is a rare form of mineralo-
corticoid resistance characterized in newborns by salt wasting with 
dehydration, hyperkalemia and failure to thrive. This disease is hetero-
geneous in etiology and includes autosomal dominant PHA1 owing 
to mutations of the NR3C2 gene encoding the mineralocorticoid 
receptor, autosomal recessive PHA1 due to mutations of the epithelial 
sodium channel (ENaC) gene, and secondary PHA1 associated with 
urinary tract diseases. Amongst these diseases, autosomal dominant 
PHA1 shows has manifestations restricted to renal tubules including 
a mild salt loss during infancy and that shows a gradual improvement 
with advancing age. Here, we report a neonatal case of PHA1 with 
a NR3C2 gene mutation (a heterozygous c.2146_2147insG in exon 
5), in which the patient showed failure to thrive, hyponatremia, 
hyperkalemia, and elevated plasma renin and aldosterone levels. This 
is the first case of pseudohypoaldosteronism type 1 confirmed by 
genetic analysis in Korea.
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mineralocorticoid receptor (MR). In addition, patients with AD-
PHA1 manifest a renal tubule-restricted target organ defect that 
includes mild salt loss during infancy and a gradual improvement 
with advancing age
4). Conversely, patients with the autosomal 
recessive form of PHA1 (AR-PHA1), which is caused by mutations 
of the amiloride-sensitive epithelial sodium channel (ENaC) gene, 
manifest severe salt wasting resulting from multiple mineralocorticoid 
target tissues including the sweat glands, salivary glands, respiratory 
tract epithelial cells and the kidneys
2). Unlike AD-PHA1, AR-PHA1 
has poor prognosis and requires life-long salt supplementation
3).
In Korea, there have been several case reports of PHA1
5-12); 
however, none of these have been confirmed by genetic analysis. Here, 
Introduction
Pseudohypoaldosteronism type 1 (PHA1) is a rare disease of 
mineralocorticoid resistance characterized by renal salt wasting, 
dehydration and failure to thrive in the neonatal period
1, 2). The 
cardinal laboratory abnormalities of PHA1 are hyponatremia, 
hyperkalemia, and metabolic acidosis despite elevated plasma renin 
activity and aldosterone levels. There are two different genetic 
forms of PHA1, an autosomal dominant form (AD-PHA1) and an 
autosomal recessive form (AR-PHA1), as well as secondary PHA1, 
which is usually associated with urological problems
2, 3). AD-PHA1 
is caused by mutations of the NR3C2 gene, which encodes the Korean J Pediatr 2011;54(2):90-93 • DOI: 10.3345/kjp.2011.54.2.90    91
we report a case of a 25 day-old boy with typical clinical features of 
PHA1 and a de novo heterozygous mutation in the NR3C2 gene 
(c.2146_2147insG in exon 5).
Case report
A 25 day-old male infant was admitted to our hospital due to 
poor weight gain and dehydration. The patient was born at full term 
with a birth weight of 2.63 kg (3–10th percentile). There were no 
perinatal problems, and the family history was unremarkable. Upon 
admission, his height was 49 cm (3–10th percentile), his weight was 
2.46 kg (<3rd percentile), and his head circumference was 34.5 cm 
(10–50th percentile). Additionally, his blood pressure was 75/41 
mmHg, pulse rate was 137/min, respiratory rate was 45/min, and 
body temperature was 36℃. The patient was alert at the time of 
admission, although his anterior fontanelle was slightly sunken and 
skin turgor was decreased. He had grossly normal external genitalia 
and other physical examination findings were unremarkable.
The initial laboratory examinations revealed the following: 
serum sodium, 122 mmol/L; serum potassium, 6.3 mmol/L; 
serum chloride, 91 mmol/L; blood urea nitrogen, 36 mg/dL; serum 
creatinine, 0.8 mg/dL; plasma renin activity, 114.1 ng/mL/hr (normal 
range 1–2.5); aldosterone, 9,840 pg/mL (normal range 50–194). 
The venous blood gas analysis revealed metabolic acidosis (pH 7.295, 
pCO2 41.3 mmHg, and HCO3
– 20.1 mmol/L). The spot urine 
sodium, potassium, chloride and creatinine levels were 16 mmol/
L, 9.7 mmol/L, 18 mmol/L and 3.3 mg/dL, respectively. Neonatal 
screening tests revealed a normal serum 17-hydroxyprogestenone 
level. Renal ultrasonography showed no abnormal findings. Genetic 
analysis revealed a heterozygous c.2146_2147insG (p.E716GfsX28) 
mutation in exon 5 of the NR3C2 gene that his parents did not have 
(Fig. 1).
The patient’s serum electrolytes levels and renal function re-
turned to normal with initial parenteral hydration and sodium 
supple  mentation for two days, and he then showed gradual weight 
gain with subsequent oral sodium chloride (Na
+ 7–10 mEq/
kg/day) supplementation. At the age of 6 months, oral sodium 
supplementation was discontinued at the outpatient clinic. The 
patient is currently nineteen-months-old and has resumed normal 
growth and development.
Discussion
Since PHA1 was first described in an infant with severe salt 
wasting syndrome by Cheek and Perry
13) in 1958, there have been a 
number of case reports and recent molecular genetic studies that have 
identified two genetically different forms of PHA1, AD-PHA1 and 
AR-PHA1
3, 4, 14, 15).
Mineralocorticoid plays a crucial role in the regulation of fluid 
or electrolyte balance and blood pressure
16). Aldosterone is secreted 
in response to hypovolemia or hyperkalemia and increases the 
acti  vity of ENaC in the kidneys by binding to intracytoplasmic 
mineralocorticoid receptor (MR)
2). Aldosterone then stimulates 
reabsorption of sodium, as well as excretion of potassium and 
hydrogen in the distal nephron. Disruption of the intracellular MR 
signaling cascade, by either MR or ENaC gene mutation, leads to 
salt wasting and causes PHA1, i.e., hyponatremia, hyperkalemia and 
metabolic acidosis
1, 16). 
Fig. 1. Partial sequencing data of the NR3C2 gene of the patient and his parents. The 
patient had a heterozygous c.2146_2147insG (p.E716GfsX28) mutation in exon 5 of 
the NR3C2 gene (panel A, 5’>3’ sense sequences; panel B, 3’>5’ complementary 
sequences). His parents (panel C, his mother; panel D, his father) did not have the 
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Since ENaC is expressed not only in the distal nephron, but also in 
the colon, sweat glands, salivary glands and lung epithelial cells, AR-
PHA1, which is caused by mutations in one of the three subunits of 
the ENaC
2, 14), presents salt wasting from these various organs as well 
as the kidneys
17). Moreover, the salt loss in AR-PHA1 is severe and 
does not improve with age; therefore, patients require massive sodium 
supplementation throughout life. 
AD-PHA1 is caused by loss-of-function mutations of the NR3C2 
gene
1, 2, 18, 20), and a significant number of the reported mutations 
are de novo mutations as shown in the present study
21-23). Although 
mutant receptors may exert some dominant negative effects on the 
wild-type receptors, haploinsufficiency is known to be sufficient to 
cause AD-PHA1
1, 2, 22). When compared to AR-PHA1, the salt loss 
in AD-PHA1 is less severe, restricted to the kidneys, and improves 
spontaneously with age. Although mild in its course, it has been 
re  ported that AD-PHA1 can be associated with a high infant 
mortality rate. Geller et al.
21) reported a number of unexplained 
deaths in infants at risk for AD-PHA1, which suggests that AD-
PHA1 is potentially fatal to neonates. Therefore, early diagnosis 
and prophylactic salt supplementation for neonates at risk for AD-
PHA1 is essential
2). Exogenous mineralocorticoid treatment has no 
effect in patients with AD-PHA1, and patients usually respond well 
to sufficient salt supplementation
19). The spontaneous resolution of 
symptoms after infancy in patients with PHA1 can be explained by 
(1) the change in diet from low-sodium human breast milk to higher 
salt diet and (2) maturation of sodium reabsorption function of the 
renal tubules with increasing age
2, 4). However, high aldosterone levels 
may persist even after normalization of other laboratory findings, 
including serum electrolyte levels in all cases
1).
Our patient presented with typical clinical findings of PHA1 
during the neonatal period and showed spontaneous improvement 
after 6 months of age. NR3C2 gene analysis revealed a de novo 
frame-shifting insertion mutation (heterozygous c.2146_2147insG 
in exon 5). There have been several case reports of PHA1 in Korea
5-12); 
however, this case is the first one that has been confirmed genetically 
(Table 1). Molecular genetic studies can provide accurate diagnosis 
as well as basic data for genetic counseling and understanding of the 
pathogenesis of PHA1. 
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